CARL Overview

Carlsmed, Inc. is a commercial-stage medical technology company providing AI-enabled personalized spine surgery solutions. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights for each surgeon. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.

Wall Street analysts forecast CARL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CARL is20.50 USD with a low forecast of 18.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Carlsmed Inc revenue for the last quarter amounts to 16.12M USD, increased 58.17

Carlsmed Inc. EPS for the last quarter amounts to -0.32 USD, increased 33.33

Carlsmed Inc (CARL) has 127 emplpoyees as of May 16 2026.

Today CARL has the market capitalization of 299.31M USD.